SLE was Teva’s predecessor, and is presently its full subsidiary, operating as a distribution unit throughout Israel and the OPT. SLE also distributes products of approximately one dozen multinational pharmaceutical companies.

The company provides logistical support for Teva’s sales and distribution activities in Israel, including the distribution of third-party products, among which are several multinational pharmaceutical companies.

As a part of the Israeli pharmaceutical industry, SLE enjoys the advantages generated by the Israeli occupation of Palestinian lands allowing the company to exploit the Palestinian market. 'Quality and Security reasons' in conjunction with economic and political justifications create a Palestinian captive market for Israeli and multinational companies.

The Paris Protocol, an annex to the Oslo Accords, which regulates the financial relations between Israel and the future Palestinian state, placed both entities under the same taxation envelope. As a result, the Palestinians continue to depend on Israeli policies, customs laws and services for the import and export of goods. This dependency has inflicted strong negative economic effects on the Palestinian pharmaceutical industry. Various hindrances generate extra costs that harm the development of the local industry: the burden of the annual licensing of imported raw materials, the costs of back-to-back deliveries to and from the WB and the GS, the costs of shipping drugs in bulk via Jordan, the exclusion of large Arab markets as well as in Israel, and the inability of the Gazan industry to develop and expand due to the prohibition on export.

SLE, likewise other Israeli and multinational companies, enjoys the aforementioned situation in several ways. The company enjoys easy access to the Palestinian market, free of customs and checkpoint, e.g. change of trucks at cargo checkpoints. SLE's agents do not have to amend any of their products in order to sell them in the OPT. Thus, the company can sell drugs that are not labeled in Arabic. SLE meets little to no competition from the cheaper generic drug industry, as a result of the Israeli Ministry of Health restrictions on drug registration in Israel and their enforcement on the Palestinian market.

For further information, check our report on the Pharmaceutical Industry: Captive economy.